Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Goodwill & Intangibles of $40.0 billion for Q1 2026, down 9.59% year-over-year from $44.2 billion in Q1 2025, and down 2.14% quarter-over-quarter from $40.9 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Goodwill & Intangibles data on file, last reported at $40.0 billion in Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $40.0 billion, down 9.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.0 billion (down 9.59% YoY), and the FY2025 annual result was $40.9 billion, down 9.26% from the prior year.
- Goodwill & Intangibles slipped to $40.0 billion in Q1 2026 per CELG-RI's latest filing, from $40.9 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $60.6 billion in Q1 2022 and troughed at $40.0 billion in Q1 2026.
- A 5-year average of $50.0 billion and a median of $50.1 billion in 2023 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles retreated 0.43% in 2024, then fell 18.85% in 2025.
- A 5-year view of Goodwill & Intangibles shows it stood at $57.0 billion in 2022, then retreated by 15.38% to $48.2 billion in 2023, then slipped by 6.66% to $45.0 billion in 2024, then slipped by 9.26% to $40.9 billion in 2025, then slipped by 2.14% to $40.0 billion in 2026.
- Business Quant data shows CELG-RI's Goodwill & Intangibles at $40.0 billion in Q1 2026, $40.9 billion in Q4 2025, and $42.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.98 Bn |
| Dec 31, 2025 | 40.86 Bn |
| Sep 30, 2025 | 42.21 Bn |
| Jun 30, 2025 | 43.15 Bn |
| Mar 31, 2025 | 44.22 Bn |
| Dec 31, 2024 | 45.03 Bn |
| Sep 30, 2024 | 48.72 Bn |
| Jun 30, 2024 | 51.16 Bn |
| Mar 31, 2024 | 54.50 Bn |
| Dec 31, 2023 | 48.24 Bn |
| Sep 30, 2023 | 50.10 Bn |
| Jun 30, 2023 | 52.47 Bn |
| Mar 31, 2023 | 54.73 Bn |
| Dec 31, 2022 | 57.01 Bn |
| Sep 30, 2022 | 59.29 Bn |
| Jun 30, 2022 | 58.14 Bn |
| Mar 31, 2022 | 60.60 Bn |
| Dec 31, 2021 | 63.03 Bn |
| Sep 30, 2021 | 65.45 Bn |
| Jun 30, 2021 | 68.59 Bn |